Over the last decade, several randomized controlled trials have also utilized plasmid and viral vectors with the VEGF gene to treat severe coronary heart disease (Euroinject One, KAT, REVASC, NOTHERN, NOVA, VEGF-A Neupogen, and GENASIS) [6,16]. This evidence concerns the gene VEGFA and coronary artery disorder.